Doublecortin and JIP3 are neural-specific counteracting regulators of dynein-mediated retrograde trafficking

  1. Lu Rao
  2. Peijun Li
  3. Xinglei Liu
  4. Qi Wang
  5. Alexander I Son
  6. Arne Gennerich  Is a corresponding author
  7. Judy Shih-Hwa Liu  Is a corresponding author
  8. Xiaoqin Fu  Is a corresponding author
  1. Albert Einstein College of Medicine, United States
  2. Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, China
  3. Brown University, United States
  4. Children's National Hospital, United States

Abstract

Mutations in the microtubule (MT)-binding protein doublecortin (DCX) or in the MT-based molecular motor dynein result in lissencephaly. However, a functional link between DCX and dynein has not been defined. Here, we demonstrate that DCX negatively regulates dynein-mediated retrograde transport in neurons from Dcx-/y or Dcx-/y;Dclk1-/- mice by reducing dynein's association with MTs and by disrupting the composition of the dynein motor complex. Previous work showed an increased binding of the adaptor protein C-Jun-amino-terminal kinase-interacting protein 3 (JIP3) to dynein in the absence of DCX. Using purified components, we demonstrate that JIP3 forms an active motor complex with dynein and its cofactor dynactin with two dyneins per complex. DCX competes with the binding of the second dynein, resulting in a velocity reduction of the complex. We conclude that DCX negatively regulates dynein-mediated retrograde transport through two critical interactions by regulating dynein binding to MTs and by regulating the composition of the dynein motor complex.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for figure 2, 3, 4, figure 2-figure supplement 1 and table 1.

The following data sets were generated

Article and author information

Author details

  1. Lu Rao

    Department of Biochemistry, Albert Einstein College of Medicine, Bronx, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Peijun Li

    Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Xinglei Liu

    Department of Neurology, Brown University, Providence, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Qi Wang

    Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Alexander I Son

    Children's National Research Institute, Children's National Hospital, Washington, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Arne Gennerich

    Department of Biochemistry, Albert Einstein College of Medicine, Bronx, United States
    For correspondence
    arne.gennerich@einsteinmed.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8346-5473
  7. Judy Shih-Hwa Liu

    Department of Neurology, Brown University, Providence, United States
    For correspondence
    judy_liu@brown.edu
    Competing interests
    The authors declare that no competing interests exist.
  8. Xiaoqin Fu

    Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
    For correspondence
    fuxq@wzhealth.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6354-8960

Funding

National Natural Science Foundation of China (81971425)

  • Xiaoqin Fu

National Natural Science Foundation of China (81871035)

  • Peijun Li

Natural Science Foundation of Zhejiang Province (LZ09H090001)

  • Peijun Li

Natural Science Foundation of Zhejiang Province (LY20H040002)

  • Xiaoqin Fu

National Institutes of Health (R01GM098469)

  • Arne Gennerich

National Institutes of Health (R01NS114636)

  • Arne Gennerich

National Institutes of Health (RO1NS104428-01)

  • Judy Shih-Hwa Liu

Brain and Behavior Research Foundation

  • Judy Shih-Hwa Liu

Whitehall Foundation

  • Judy Shih-Hwa Liu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal procedures were approved by the Committee on the Ethics of Animal Experiments of Wenzhou Medical University (Permit number: wydw2019-0723).

Copyright

© 2022, Rao et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,401
    views
  • 229
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lu Rao
  2. Peijun Li
  3. Xinglei Liu
  4. Qi Wang
  5. Alexander I Son
  6. Arne Gennerich
  7. Judy Shih-Hwa Liu
  8. Xiaoqin Fu
(2022)
Doublecortin and JIP3 are neural-specific counteracting regulators of dynein-mediated retrograde trafficking
eLife 11:e82218.
https://doi.org/10.7554/eLife.82218

Share this article

https://doi.org/10.7554/eLife.82218

Further reading

    1. Cell Biology
    Affiong Ika Oqua, Kin Chao ... Alejandra Tomas
    Research Article

    G protein-coupled receptors (GPCRs) are integral membrane proteins which closely interact with their plasma membrane lipid microenvironment. Cholesterol is a lipid enriched at the plasma membrane with pivotal roles in the control of membrane fluidity and maintenance of membrane microarchitecture, directly impacting on GPCR stability, dynamics, and function. Cholesterol extraction from pancreatic beta cells has previously been shown to disrupt the internalisation, clustering, and cAMP responses of the glucagon-like peptide-1 receptor (GLP-1R), a class B1 GPCR with key roles in the control of blood glucose levels via the potentiation of insulin secretion in beta cells and weight reduction via the modulation of brain appetite control centres. Here, we unveil the detrimental effect of a high cholesterol diet on GLP-1R-dependent glucoregulation in vivo, and the improvement in GLP-1R function that a reduction in cholesterol synthesis using simvastatin exerts in pancreatic islets. We next identify and map sites of cholesterol high occupancy and residence time on active vs inactive GLP-1Rs using coarse-grained molecular dynamics (cgMD) simulations, followed by a screen of key residues selected from these sites and detailed analyses of the effects of mutating one of these, Val229, to alanine on GLP-1R-cholesterol interactions, plasma membrane behaviours, clustering, trafficking and signalling in INS-1 832/3 rat pancreatic beta cells and primary mouse islets, unveiling an improved insulin secretion profile for the V229A mutant receptor. This study (1) highlights the role of cholesterol in regulating GLP-1R responses in vivo; (2) provides a detailed map of GLP-1R - cholesterol binding sites in model membranes; (3) validates their functional relevance in beta cells; and (4) highlights their potential as locations for the rational design of novel allosteric modulators with the capacity to fine-tune GLP-1R responses.

    1. Cell Biology
    2. Genetics and Genomics
    Keva Li, Nicholas Tolman ... UK Biobank Eye and Vision Consortium
    Research Article

    A glaucoma polygenic risk score (PRS) can effectively identify disease risk, but some individuals with high PRS do not develop glaucoma. Factors contributing to this resilience remain unclear. Using 4,658 glaucoma cases and 113,040 controls in a cross-sectional study of the UK Biobank, we investigated whether plasma metabolites enhanced glaucoma prediction and if a metabolomic signature of resilience in high-genetic-risk individuals existed. Logistic regression models incorporating 168 NMR-based metabolites into PRS-based glaucoma assessments were developed, with multiple comparison corrections applied. While metabolites weakly predicted glaucoma (Area Under the Curve = 0.579), they offered marginal prediction improvement in PRS-only-based models (p=0.004). We identified a metabolomic signature associated with resilience in the top glaucoma PRS decile, with elevated glycolysis-related metabolites—lactate (p=8.8E-12), pyruvate (p=1.9E-10), and citrate (p=0.02)—linked to reduced glaucoma prevalence. These metabolites combined significantly modified the PRS-glaucoma relationship (Pinteraction = 0.011). Higher total resilience metabolite levels within the highest PRS quartile corresponded to lower glaucoma prevalence (Odds Ratiohighest vs. lowest total resilience metabolite quartile=0.71, 95% Confidence Interval = 0.64–0.80). As pyruvate is a foundational metabolite linking glycolysis to tricarboxylic acid cycle metabolism and ATP generation, we pursued experimental validation for this putative resilience biomarker in a human-relevant Mus musculus glaucoma model. Dietary pyruvate mitigated elevated intraocular pressure (p=0.002) and optic nerve damage (p<0.0003) in Lmx1bV265D mice. These findings highlight the protective role of pyruvate-related metabolism against glaucoma and suggest potential avenues for therapeutic intervention.